Development of Preclinical Models Derived From Tumors With a Molecular Abnormality of Interest to Test Their Sensitivity to New Anti-tumor Therapies.

What this Trial Is About

Researchers are developing new laboratory models called spheroids from tumor samples of patients who have a specific mutation of interest. These spheroids are designed to mimic the original tumor and help study how the tumor responds to various anti-cancer treatments. The study focuses on patients with malignant tumors at advanced stages who are undergoing routine biopsies or surgeries to collect tumor tissue. Participants will have a biopsy or surgery as part of their regular medical care, during which a portion of their tumor sample will be sent to a specialized laboratory to create the spheroids. Additionally, a blood sample of 38 mL will be collected to evaluate potential blood-related toxicities of drugs and to explore connections between disease stage and exosome levels. The study involves only one group of participants undergoing these procedures. Throughout the study, researchers will monitor the development and stability of the spheroids, ensuring they accurately represent the tumors characteristics. They will use these models to test the effectiveness of different therapeutic molecules on the tumor cells. The primary outcome is the successful creation of spheroids within one month. Blood analyses and tumor response assessments are also part of the study. Participation includes signing informed consent and providing samples during scheduled medical procedures, with a study duration extending up to July 2030.

Development of Preclinical Models Derived From Tumors With a Molecular Abnormality of Interest to Test Their Sensitivity to New Anti-tumor Therapies.